WeTrials
Active, not recruiting

A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations

What is this study?

This study is testing a new medication called sacituzumab tirumotecan compared to standard chemotherapy for people with advanced lung cancer. Researchers want to see if this new treatment can help patients live longer and better manage their cancer after other treatments have stopped working.

Who can participate?

You may be able to join if you have advanced non-squamous non-small cell lung cancer with specific gene changes, and your cancer has grown after previous treatments. However, people with certain eye conditions, severe nerve damage, or other specific lung cancer types cannot participate.

What will happen?

Participants will be randomly chosen to receive either the new study drug or a standard chemotherapy medication. Your health and tumor growth will be closely monitored through regular imaging scans and check-ups with the study team.

Where and when?

This study has locations in places like Los Angeles, California, and Jacksonville and Orange City, Florida. The study is currently active but not actively recruiting new patients at this time.

Key Points
  • 1Testing a new cancer-fighting drug against standard chemotherapy
  • 2For patients with specific gene mutations who tried previous treatments
  • 3Study is currently active but not recruiting new participants

No related links yet

Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Non-small Cell Lung Cancer (NSCLC)

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.